AxoGen, Inc. (NASDAQ:AXGN) CEO Sells $301,670.40 in Stock

AxoGen, Inc. (NASDAQ:AXGN) CEO Karen L. Zaderej sold 39,280 shares of AxoGen stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $7.68, for a total transaction of $301,670.40. Following the completion of the sale, the chief executive officer now owns 1,124,565 shares of the company’s stock, valued at approximately $8,636,659.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

AxoGen Trading Up 2.9 %

Shares of AxoGen stock opened at $7.77 on Thursday. The firm has a market capitalization of $335.74 million, a PE ratio of -14.94 and a beta of 1.07. The company has a current ratio of 2.89, a quick ratio of 2.14 and a debt-to-equity ratio of 0.71. The firm’s 50 day moving average is $9.26 and its 200 day moving average is $7.03. AxoGen, Inc. has a 1 year low of $3.45 and a 1 year high of $10.83.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AXGN. Cantor Fitzgerald restated an “overweight” rating and issued a $12.00 target price on shares of AxoGen in a research report on Friday, January 19th. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 target price on shares of AxoGen in a research report on Thursday, December 7th. Finally, StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Wednesday, February 28th.

Institutional Investors Weigh In On AxoGen

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Envestnet Asset Management Inc. grew its holdings in shares of AxoGen by 2.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 42,906 shares of the medical equipment provider’s stock valued at $351,000 after purchasing an additional 1,187 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of AxoGen by 12.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,795 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 1,450 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of AxoGen by 2.9% during the 2nd quarter. Rhumbline Advisers now owns 54,379 shares of the medical equipment provider’s stock valued at $496,000 after purchasing an additional 1,527 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of AxoGen by 7.2% during the 4th quarter. JPMorgan Chase & Co. now owns 23,912 shares of the medical equipment provider’s stock valued at $238,000 after purchasing an additional 1,612 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of AxoGen by 0.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 296,989 shares of the medical equipment provider’s stock valued at $2,359,000 after purchasing an additional 2,193 shares during the last quarter. 80.29% of the stock is owned by institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.